戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e to up to 31 drugs within 5 days after bone marrow biopsy.
2 ith tryptase in estimating the need for bone marrow biopsy.
3  aggregates, and atypical mast cells on bone marrow biopsy.
4 94% and 100% for PET-CT and 40% and 100% for marrow biopsy.
5 ent accuracy to replace routine staging bone marrow biopsy.
6 2, t[8;21][q22;q22.1]) was diagnosed on bone marrow biopsy.
7 e of biopsy site than the usual random iliac marrow biopsy.
8 ne and serum immunoelectrophoresis, and bone marrow biopsy.
9 diagnosis usually depends on results of bone marrow biopsy.
10 mastocytosis) and thus candidates for a bone marrow biopsy.
11 the potential to reduce the need for staging marrow biopsy.
12 re red cell aplasia (PRCA) confirmed by bone marrow biopsy.
13  with hematologic response criteria and bone marrow biopsies.
14 ot density compared with normal control bone marrow biopsies.
15  relevance of expression in 55 archival bone marrow biopsies.
16 loid leukemia (AML) routinely undergo a bone marrow biopsy 7-10 days after induction chemotherapy to
17                             Analysis of bone marrow biopsies after CTL019 revealed 8 patients with pe
18 Response was assessed by weekly CBC and bone marrow biopsy after cycle 2 and after each subsequent cy
19                                         Bone marrow biopsy analysis showed 5% plasma cells, which sta
20                                         Bone marrow biopsies and imaging were performed by cycle 8 an
21 tochemically by factor VIII staining of bone marrow biopsies and quantified by assessment of microves
22 s of blood vessels were measured in 145 bone marrow biopsies and the levels of vascular endothelial g
23               Five patients were upstaged by marrow biopsy and 7 by contrast-enhanced CT in the bowel
24 nts with low-risk MGUS can safely defer bone marrow biopsy and advanced imaging, and should undergo p
25                           The patient's bone marrow biopsy and aspirate displayed unique pathologic f
26 and negligible gene marking, diagnostic bone marrow biopsy and aspirate were performed at day 88.
27                                       A bone marrow biopsy and aspiration revealed a mildly hypercell
28  myeloma was diagnosed and confirmed by bone marrow biopsy and aspiration.
29 iate- and high-risk MGUS should trigger bone marrow biopsy and bone imaging to detect overt MM and sh
30                      Congo red stain on bone marrow biopsy and fat pad aspirate was negative for amyl
31  ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or plac
32  ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or plac
33 up consisted of a complete blood count, bone marrow biopsy, and immunohistochemical and histochemical
34 is, in the selection of those needing a bone marrow biopsy, and in the documentation of disease progr
35 2005 had data extracted from staging PET-CT, marrow biopsy, and treatment records.
36 o identify those patients who require a bone marrow biopsy, and whether the pathogenesis of IA involv
37 suspicious lymphocytic infiltrates in a bone marrow biopsy as the sole suggestion of residual disease
38 adioimmunotherapy, after lymph node and bone marrow biopsies at 2-4 and/or 19 h after injection.
39 ing, as well as follow-up allograft and bone marrow biopsies at 3 and 9 months, including analyses of
40 he diagnosis of 661 PMF patients with a bone marrow biopsy at presentation was revised according to m
41 etastatic CRPC who underwent transiliac bone marrow biopsy between October 2007 and March 2010.
42                                         Bone marrow biopsies (BMB) are performed before/after therapy
43 ll lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marrow inv
44                                Skin and bone marrow biopsies can thus be used to generate de novo fun
45 an IgG kappa monoclonal gammopathy, and bone marrow biopsy confirmed smoldering multiple myeloma with
46   A percutaneous biopsy of the mass and bone marrow biopsy confirmed the diagnosis of primary adrenal
47 rum paraproteins and/or light chains or bone marrow biopsy defined response.
48 inal mass was discovered, and tumor and bone marrow biopsies disclosed rhabdomyosarcoma.
49  transformed plasma cells from the same bone marrow biopsy enables discovery of patient-specific tran
50 ide therapy should undergo surveillance bone marrow biopsy every 2 to 3 years and that those who show
51                                         Bone marrow biopsy exhibited mostly mixed patterns of small B
52 icaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggregates
53 ed at the protein level by immunostaining of marrow biopsies for NY-ESO-1.
54  MCAS-T underwent evaluation, including bone marrow biopsy, for a MC disorder.
55 esis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients.
56 comprehensive proteogenomic analysis of bone marrow biopsies from 252 uniformly treated AML patients
57                            We evaluated bone marrow biopsies from 40 children with newly diagnosed, u
58 n factor (MITF), is highly expressed in bone marrow biopsies from 9 of 10 patients with systemic mast
59         Immunohistochemical staining of bone marrow biopsies from most of these patients revealed abe
60                           Evaluation of bone marrow biopsies from myeloma patients revealed a strong
61                   Moreover, analysis of bone marrow biopsies from myeloma patients reveals a positive
62                                      In bone marrow biopsies from patients with DBA or del(5q) myelod
63                                         Bone marrow biopsies from patients with multiple myeloma reve
64                                         Bone marrow biopsies from patients with systemic mastocytosis
65 taneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cytokin
66 tochemical paraffin section staining of bone marrow biopsies in the staging of B-cell malignant lymph
67                                Although bone marrow biopsies in these patients showed increased numbe
68 imal test indicating the necessity of a bone marrow biopsy in ISM-suspected patients.
69 only used test to estimate the need for bone marrow biopsy in patients suspected to have indolent sys
70                                         Bone marrow biopsy in patients with prolonged or late cytopen
71 r DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogeneity
72 ected by immunohistochemistry in normal bone marrow biopsies, indicating an in vivo function.
73  response to therapy; also, the role of bone marrow biopsy is being revisited.
74                                       A bone marrow biopsy is no longer indicated for the routine sta
75 of variable symptoms until confirmatory bone marrow biopsy is performed.
76                                         Bone marrow biopsies largely replaced by PCa were analyzed us
77                                         Bone marrow biopsy may reveal hemophagocytosis and marrow his
78 TA-anti-CD45 antibody (BC8) imaging and bone marrow biopsy measurements to ascertain the biodistribut
79 se activity in the plasma isolated from bone marrow biopsies of 100 patients reveals 86 positive for
80 dominant clonotypes in blood and in historic marrow biopsies of 35 AA, 37 MDS, and 21 paroxysmal noct
81 quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilitate i
82  cutoff correctly classifies diagnostic bone marrow biopsies of MPN,U patients specified upon follow-
83                  In this investigation, bone marrow biopsies of the anterior iliac crest were examine
84              Responses were assessed by bone marrow biopsy on day 15 of the first course and by clini
85 alth record; review of laboratory data; bone marrow biopsy pathology analysis; and in vitro enzymatic
86  features with the exception that their bone marrow biopsy pathology revealed abundant neutrophils co
87 ased risk of identifying pathology on a bone marrow biopsy performed for a low WBC count (odds-ratio
88                                         Bone marrow biopsy performed in two of these five patients sh
89  post-treatment assessments were serial bone-marrow biopsy, peripheral blood collections, staging, se
90 Cr corresponded with the high degree of bone marrow biopsies positive for atypical mast cells, the pr
91 aged using clinical assessment, CT, and bone marrow biopsy (RATHL stage).
92                                         Bone marrow biopsy revealed hypercellular marrow.
93                                         Bone marrow biopsy revealed no evidence of infectious or neop
94                  MAC loads in bilateral bone marrow biopsy samples from 7 subjects were highly correl
95 ine model of Ph+ B-ALL as well as human bone marrow biopsy samples to assess the fundamental nature o
96 /mL, <15% infiltration by mast cells in bone marrow biopsy-sections, and diagnosis of ISM were identi
97                          Early in treatment, marrow biopsies showed increased megakaryocyte number an
98                                  Serial bone marrow biopsies showed normalization of trilineage hemat
99                         Comparison with bone marrow biopsies showed that FDG-PET was not reliable for
100                                         Bone marrow biopsy showed 60% infiltration with lambda light
101                 Immunohistochemistry of bone marrow biopsy showed an increased number of plasma cells
102           Complete clinical staging and bone marrow biopsy showed no signs of disseminated disease.
103                            In 3 patients the marrow biopsy specimen was positive but the PET scan nor
104        After histologic analysis of the bone marrow biopsy specimen, diagnosis of Waldenstrom macrogl
105                          In this study, bone marrow biopsy specimens from 36 patients with T-cell GLL
106  TMA was constructed using pretreatment bone marrow biopsy specimens from 64 adult patients with ALL.
107 e were detected on peripheral smear and bone marrow biopsy specimens, and PCR amplified Ehrlichia ewi
108 gs, and immunohistochemical staining of bone marrow biopsy specimens.
109                             Analysis of bone marrow-biopsy specimens obtained from two patients at th
110         Immunohistochemical analysis of bone marrow-biopsy specimens showed that only myeloma cells c
111                 These data suggest that bone marrow biopsy using antigen-targeted magnetic nanopartic
112                                         Bone marrow biopsy was done on day -7 to estimate radiation d
113  nondiagnostic, and lumbar puncture and bone marrow biopsies were negative.
114                                         Bone marrow biopsies were obtained 14-24 h after infusion, an
115                       With informed consent, marrow biopsies were obtained to collect prostate tumor.
116                 One hundred eighty-four bone marrow biopsies were obtained, and 48 had prostate tumor
117                  Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer pati
118 onoclone of IgG1, the patient underwent bone marrow biopsy which revealed Monoclonal Gammopathy of re
119  has historically been limited by infrequent marrow biopsies, which increase the risk of infections a
120 GFR-expressing tumor declined on serial bone marrow biopsies with combination therapy alone.

 
Page Top